Passa al contenuto
Merck

P1750000

Pimozide

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

150 MG

113,00 €

113,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine in blocco

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C28H29F2N3O
Numero CAS:
Peso molecolare:
461.55
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Nome del prodotto

Pimozide, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)

SMILES string

Fc1ccc(cc1)C(CCCN2CCC(CC2)N3C(=O)Nc4ccccc34)c5ccc(F)cc5

InChI key

YVUQSNJEYSNKRX-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

pimozide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
BP6821539508PHR3223
Pimozide European Pharmacopoeia (EP) Reference Standard

P1750000

Pimozide

Pimozide British Pharmacopoeia (BP) Reference Standard

BP682

Pimozide

Pimozide United States Pharmacopeia (USP) Reference Standard

USP

1539508

Pimozide

Pimozide pharmaceutical secondary standard, certified reference material

Supelco

PHR3223

Pimozide

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

manufacturer/tradename

EDQM

manufacturer/tradename

BP

manufacturer/tradename

USP

manufacturer/tradename

-

format

neat

format

neat

format

neat

format

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

API family

pimozide

API family

pimozide

API family

pimozide

API family

-

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

-

storage temp.

-

Application

Pimozide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

related product

N° Catalogo
Descrizione
Determinazione del prezzo

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

R M Pinder et al.
Drugs, 12(1), 1-40 (1976-01-01)
Pimozide 1-(1-[4,4-bis(4-fluorophenyl)butyl]-4-peperidinyl)-2-benzimidazolone, is the first of a new series of psychotropic drugs, the kiphenylbutylpiperidines. It is advocated for once-daily use as maintenance therapy in chronic schizophrenia and for the treatment of psychic and functional disorders induced by personality traits. Published
C Sprissler et al.
Blood cancer journal, 4, e240-e240 (2014-08-26)
The spleen tyrosine kinase (SYK) was identified as an oncogenic driver in a broad spectrum of hematologic malignancies. The in vivo comparison of three SYK containing oncogenes, SYK(wt), TEL-SYK and IL-2-inducible T-cell kinase (ITK)-SYK revealed a general myeloexpansion and the
L A Opler et al.
The Journal of clinical psychiatry, 52(5), 221-233 (1991-05-01)
Pimozide, a diphenylbutylpiperidine neuroleptic which is FDA-approved as a backup treatment for Gilles de la Tourette's syndrome, has been used abroad for many years as a treatment of schizophrenia and has been recently reported to be particularly effective in treating
Meghana Mothi et al.
The Cochrane database of systematic reviews, 11(11), CD001949-CD001949 (2013-11-07)
Pimozide, formulated in the 1960s, continues to be marketed for the care of people with schizophrenia or related psychoses such as delusional disorder. It has been associated with cardiotoxicity and sudden unexplained death. Electrocardiogram monitoring is now required before and
C L Colvin et al.
Drug intelligence & clinical pharmacy, 19(6), 421-424 (1985-06-01)
The orphan drug pimozide was recently approved for marketing in the U.S. for the treatment of Tourette's syndrome (TS). TS is characterized by recurrent, involuntary motor movements and vocal tics, and is believed to be due to neurochemical dysfunction. Pimozide's

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica